We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biogen (BIIB) Beats Revenues and Earnings Estimates in Q4
Read MoreHide Full Article
Cambridge, MA-based Biogen Inc. (BIIB - Free Report) holds a strong position in the multiple sclerosis (“MS”) market with a wide range of products including Avonex, Tysabri, Tecfidera and Plegridy. However, as competition in the MS market intensifies, Biogen is trying to diversify beyond MS to other areas like Alzheimer's, Parkinson's, stroke, among others.
Biogen’s earnings performance has been decent so far. The company delivered a positive surprise in three of the last four quarters. The average earnings beat over the last four quarters is 4.66%.
Currently, Biogen has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Biogen’s fourth quarter 2018 earnings beat expectations. The company posted earnings of $6.99 per share while our consensus called for EPS of $6.72.
Revenues Beat: Biogen posted revenues of $3.53 billion, beating the consensus estimate of $3.39 billion. Revenue increased 7% year over year.
Key Statistics: The company's oral MS drug Tecfidera’s sales rose 3% year over year to $1.10 billion. The other MS drug, Tysabri’s sales were flat year over year at $464 million. Spinraza (spinal muscular atrophy) sales grew 30% year over year to $469.9 million driven by sales growth in both United States and in ex U.S. markets.
Pre-Market Trading: Shares decreased 0.46% in pre-market trading.
Check back later for our full write up on this BIIB earnings report later!
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Biogen (BIIB) Beats Revenues and Earnings Estimates in Q4
Cambridge, MA-based Biogen Inc. (BIIB - Free Report) holds a strong position in the multiple sclerosis (“MS”) market with a wide range of products including Avonex, Tysabri, Tecfidera and Plegridy. However, as competition in the MS market intensifies, Biogen is trying to diversify beyond MS to other areas like Alzheimer's, Parkinson's, stroke, among others.
Biogen’s earnings performance has been decent so far. The company delivered a positive surprise in three of the last four quarters. The average earnings beat over the last four quarters is 4.66%.
Currently, Biogen has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Biogen’s fourth quarter 2018 earnings beat expectations. The company posted earnings of $6.99 per share while our consensus called for EPS of $6.72.
Revenues Beat: Biogen posted revenues of $3.53 billion, beating the consensus estimate of $3.39 billion. Revenue increased 7% year over year.
Key Statistics: The company's oral MS drug Tecfidera’s sales rose 3% year over year to $1.10 billion. The other MS drug, Tysabri’s sales were flat year over year at $464 million. Spinraza (spinal muscular atrophy) sales grew 30% year over year to $469.9 million driven by sales growth in both United States and in ex U.S. markets.
Pre-Market Trading: Shares decreased 0.46% in pre-market trading.
Check back later for our full write up on this BIIB earnings report later!
Biogen Inc. Price and EPS Surprise
Biogen Inc. Price and EPS Surprise | Biogen Inc. Quote
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>